These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A personal initiative for women's health: to challenge the Women's Health Initiative. Genazzani AR, Gambacciani M. Gynecol Endocrinol; 2002 Aug; 16(4):255-7. PubMed ID: 12396552 [No Abstract] [Full Text] [Related]
6. Hormone replacement therapy: need for reappraisal. Nath J. Natl Med J India; 2002 Aug; 15(6):346-8. PubMed ID: 12540069 [No Abstract] [Full Text] [Related]
7. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy? Shulman LP. J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108 [No Abstract] [Full Text] [Related]
8. Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited. Pines A, Sturdee DW, Birkhäuser MH, International Menopause Society. Climacteric; 2007 Jun; 10(3):195-6. PubMed ID: 17487646 [No Abstract] [Full Text] [Related]
9. Vasomotor symptoms and mortality: the Rancho Bernardo Study. Svartberg J, von Mühlen D, Kritz-Silverstein D, Barrett-Connor E. Menopause; 2009 Jun; 16(5):888-91. PubMed ID: 19421076 [Abstract] [Full Text] [Related]
10. Postmenopausal hormone replacement therapy and the prevention of cardiovascular disease: a review. Abramson BL. J Cardiovasc Risk; 2002 Dec; 9(6):309-14. PubMed ID: 12478199 [Abstract] [Full Text] [Related]
11. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. Rosano GM, Maffei S, Andreassi MG, Vitale C, Vassalle C, Gambacciani M, Stramba-Badiale M, Mercuro G. J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119 [Abstract] [Full Text] [Related]
13. Menopause. A flash of concern. Wingert P. Newsweek; 2007 Apr 16; 149(16):16. PubMed ID: 17477154 [No Abstract] [Full Text] [Related]
14. Where are we with postmenopausal hormone therapy in 2005? Lam PM, Chung TK, Haines C. Gynecol Endocrinol; 2005 Nov 16; 21(5):248-56. PubMed ID: 16373243 [Abstract] [Full Text] [Related]
15. Adiposity and reporting of vasomotor symptoms among midlife women: the study of women's health across the nation. Thurston RC, Sowers MR, Chang Y, Sternfeld B, Gold EB, Johnston JM, Matthews KA. Am J Epidemiol; 2008 Jan 01; 167(1):78-85. PubMed ID: 17881385 [Abstract] [Full Text] [Related]
16. Clinical appraisal of the Women's Health Initiative. Speroff L. J Obstet Gynaecol Res; 2005 Apr 01; 31(2):80-93. PubMed ID: 15771632 [No Abstract] [Full Text] [Related]
17. Soy isoflavones for postmenopausal symptoms. An examination of evidence. Hulem R, Blair RM. Adv Nurse Pract; 2006 May 01; 14(5):32-8; quiz 39. PubMed ID: 16972423 [No Abstract] [Full Text] [Related]
19. [Conjugated estrogen-gestagen does not reduce cardiovascular morbidity. Were these findings (in the Women's Health Initiative study) really unexpected?]. Henriksson P. Lakartidningen; 2002 Nov 21; 99(47):4716-9. PubMed ID: 12523045 [No Abstract] [Full Text] [Related]
20. [What to think of postmenopausal hormone replacement therapy after 2002? ]. Ringa V, Uzan S. Rev Epidemiol Sante Publique; 2003 Feb 21; 51(1 Pt 1):86-9. PubMed ID: 12718317 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]